GlassScriptPhysician profile
Willie M Deas
NPI 1225146830
$2,260.67
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $496 · 2021: $760 · 2022: $451 · 2023: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $365.45 | 2021-2023 | |
| Novo Nordisk INC | $209.73 | 2019-2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.26 | 2020-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $201.26 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $197.81 | 2019-2022 | |
| Lilly USA, LLC | $134.99 | 2020-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $111.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $93.28 | 2020-2023 | Verquvo |
| Dexcom, INC. | $93.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $90.19 | 2019-2022 | |
| Abbvie INC. | $79.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $65.69 | 2020-2021 | |
| Daiichi Sankyo INC. | $64.71 | 2020-2023 | Injectafer |
| Pfizer INC. | $47.63 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.81 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $35.43 | 2022 | |
| Glaxosmithkline, LLC. | $29.77 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Allergan, INC. | $25.52 | 2020 | |
| Exact Sciences Corporation | $22.38 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $19.96 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.75 | 2023 | Gvoke Hypopen |
| Mylan Specialty L.P. | $18.76 | 2023 | Yupelri |
| Eyevance Pharmaceuticals LLC | $15.54 | 2021 | |
| Hikma Pharmaceuticals USA | $15.54 | 2021 | |
| Ibsa Pharma INC. | $14.45 | 2023 | Tirosint, Licart |
| Paratek Pharmaceuticals, INC. | $13.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.40 | 2021 | |
| Amgen INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Deas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.